“North America is the world’s biggest market for health foods, health science and it is a hub of innovation, as well as the market with various health needs,” said Minakata during the press conference. Explore related questionsThe decision to enter North America now also comes as Kirin’s health science business became profitable for the first time in FY2025. “Last year, we were fortunate that the health science business became profitable, and we are now at the stage to challenge the next level of growth,” said Minakata. Revenue of Kirin’s health science business grew 43.4% to JPY251.4bn (US$1.6bn) in FY25. Since April this year, Kirin also began operating a new entity named Kirin Health Science International to oversee Kirin’s B2C health science business outside of Japan.